ChainA, Crystal Structure Of Map Kinase P38 Complexed To The Docking Site On Its Nuclear Substrate Mef2a

Chain A, Crystal Structure Of Map Kinase P38 Complexed To The Docking Site On Its Activator Mkk3b

Chain A, Structure Of Map Kinase In Complex With A Docking Peptide

ChainA, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (monoclinic Crystal Form)

Chain A, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (tetragonal Crystal Form)

Chain B, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (tetragonal Crystal Form)

Chain C, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (tetragonal Crystal Form)

Chain D, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (tetragonal Crystal Form)

Chain A, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (tetragonal Crystal Form With Bound Sulphate)

Chain B, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (tetragonal Crystal Form With Bound Sulphate)

Chain C, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (tetragonal Crystal Form With Bound Sulphate)

Chain D, Structural Basis Of Autoactivation Of P38 Alpha Induced By Tab1 (tetragonal Crystal Form With Bound Sulphate)

Chain A, Crystal Structure Of P38 Alpha Mapk14 In Complex With Vpc00628

ChainA, Crystal Structure Of P38alpha In Complex With A Mapk Docking Partner

Chain A, The Structure Of The Map Kinase P38 At 2.1 Angstroms Resolution

ChainA, Mutated Mouse P38 Map Kinase Domain In Complex With Inhibitor Pg- 892579

Chain A, Mutated Map Kinase P38 (mus Musculus) In Complex With Inhbitor Pg- 951717

ChainA, The Third Conformation Of P38a Map Kinase Observed In Phosphorylated P38a And In Solution

ChainA, Crystal structure of a P38alpha T185G mutant in complex with TAB1 peptide.

ChainA, Crystal structure of p38 MAP kinase in complex with a dihydroquinazolinone inhibitor

Chain A, The Structure Of P38 Alpha In Complex With A Pyridinylimidazole Inhibitor

Chain A, The Structure Of P38 Alpha In Complex With A Dihydropyrido-pyrimidine Inhibitor

Chain A, Crystal Structure Of P38 Alpha In Complex With A Selective Pyridazine Inhibitor

Chain A, Crystal Structure Of The P38a-Mapkap Kinase 2 Heterodimer

Chain D, Crystal Structure Of The P38a-Mapkap Kinase 2 Heterodimer

Chain A, Crystal Structure Of The P38a-mapkap Kinase 2 Heterodimer

Chain B, Crystal Structure Of The P38a-mapkap Kinase 2 Heterodimer

Chain A, Structure Of Apo, Unphosphorylated, P38 Mitogen Activated Protein Kinase P38 (P38 Map Kinase) The Mammalian Homologue Of The Yeast Hog1 Protein

Chain X, Crystal Structure Of P38 Kinase Bound To Pyrimido-Pyridazinone Inhibitor

Chain A, Crystal Structure Of P38a Mitogen-Activated Protein Kinase In Complex With A Pyrazolopyridinone Inhibitor

Chain A, Crystal Structure Of P38a Mitogen-Activated Protein Kinase In Complex With A Pyrazolopyridazine Inhibitor

Chain A, Crystal Structure Of P38a Mitogen-Activated Protein Kinase In Complex With A Pyrazolopyridinone Inhibitor.

Chain A, Human P38 Map Kinase In Complex With 2-Amino-Phenylamino- Dibenzosuberone

Chain A, Crystal Structure Of P38a Mitogen-Activated Protein Kinase In Complex With A Triazolopyridazinone Inhibitor

Chain A, Human P38 Map Kinase In Complex With 2-Amino-Phenylamino-Benzophenone

Chain A, Human P38 Map Kinase In Complex With A Benzamide Substituted Benzosuberone

Chain A, Human P38 Map Kinase In Complex With A Dibenzosuberone Derivative

Chain A, Human P38 Map Kinase In Complex With Dibenzosuberone Compound 1

ChainA, Crystal Structure Of A N-Phenyl-N'-Naphthylurea Analog In Complex With P38 Map Kinase

Chain A, Structural basis for kinase selectivity of three clinical p38alpha inhibitors

ChainA, Structure Of Inactive Mapk14 With Ordered Activation Loop

ChainA, The Structure Of P38 Mitogen-Activated Protein Kinase In Complex With 4-[3-Methylsulfanylanilino]-6,7- Dimethoxyquinazoline

Chain A, P38 Kinase Crystal Structure In Complex With Small Molecule Inhibitor

Chain A, p38 Kinase crystal structure in complex with small molecule inhibitor

Chain A, Two Classes Of P38alpha Map Kinase Inhibitors Having A Common Diphenylether Core But Exhibiting Divergent Binding Modes

Chain A, Identification Of Novel P38 Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation.

Chain A, Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.

Chain A, Crystal Structure Of P38 In Complex With 4-Anilino Quinoline Inhibitor

Chain A, Crystal Structure Of P38 In Complex With Biphenyl Amide Inhibitor

Chain A, Crystal Structure of Human p38alpha complexed with SD-0006

Chain A, Crystal Structure Of Human P38alpha Complexed With Ph-797804

Chain A, Crystal Structure of Human p38alpha complexed with a pyridinone compound

Chain A, Crystal Structure of Human p38alpha complexed with a pyrimidopyridazinone compound

Chain A, Crystal Structure of Human p38alpha Complexed With a Triazolopyrimidine compound

Chain A, Mutagenesis Of P38 Map Kinase Eshtablishes Key Roles Of Phe169 In Function And Structural Dynamics And Reveals A Novel Dfg-Out State

Chain A, Crystal Structure Of Human P38 Alpha Complexed With A Pyrimidinone Compound

Chain A, The crystal structure of p38a MAP kinase in complex with PIA24

Chain B, Structure Of Mapk14 With Bound The Kim Domain Of The Toxoplasma Protein Gra24

Chain A, Structure Of Mapk14 With Bound The Kim Domain Of The Toxoplasma Protein Gra24

Chain A, Human P38alpha Mapk In Complex With Imidazolyl Pyridine Inhibitor 11b

Chain A, Human P38alpha Map Kinase In Complex With Dibenzosuberone Compound 2

Chain A, Dibenzooxepinone Inhibitor 12b In Complex With P38 Mapk

Chain A, Crystal Structure Of P38alpha In Complex With Lipid Pocket Ligand 9c

Chain A, Crystal Structure Of P38alpha In Complex With Lipid Pocket Ligand 9g

Chain A, Crystal Structure Of P38alpha In Complex With Lipid Pocket Ligand 9h

Chain A, Crystal Structure Of P38alpha In Complex With Lipid Pocket Ligand 9j

Chain A, Crystal Structure Of P38alpha In Complex With Lipid Pocket Ligand 9l

Chain A, Crystal Structure Of P38alpha In Complex With Lipid Pocket Ligand 9m

ChainA, P38 Kinase Crystal Structure In Complex With Small Molecule Inhibitor

ChainA, Joint Nmr And X-Ray Refinement Reveals The Structure Of A Novel Dibenzo[a,D]cycloheptenone InhibitorP38 MAP KINASE COMPLEX IN Solution

Chain A, P38 Alpha Map Kinase Inhibitor Based On Heterobicyclic Scaffolds

Chain A, Phenylalanine Pyrrolotriazine P38 Alpha Map Kinase Inhibitor Compound 11b

Chain A, Phenylalanine Pyrrolotriazine P38 Alpha Map Kinase Inhibitor Compound 11j

Chain A, P38 Alpha Map Kinase Complexed With A Benzothiazole Based Inhibitor

Chain A, Morpholino Pyrrolotriazine P38 Alpha Map Kinase Inhibitor Compound 30

Chain A, Morpholino Pyrrolotriazine P38 Alpha Map Kinase Inhibitor Compound 2

Chain A, P38 Alpha Kinase Complexed With A Pyrazolo-Pyrimidine Based Inhibitor

Chain A, P38 Alpha Kinase Complexed With A 2-aminothiazol-5-yl-pyrimidine Based Inhibitor

Chain A, P38 Alpha Map Kinase Complexed With Pyrrolotriazine Inhibitor 7k

Chain B, P38 Alpha Map Kinase Complexed With Pyrrolotriazine Inhibitor 7k

Chain A, P38 Alpha Map Kinase Complexed With Pyrrolotriazine Inhibitor 7v

Chain B, P38 Alpha Map Kinase Complexed With Pyrrolotriazine Inhibitor 7v

Chain A, P38 Alpha Kinase Complexed With A 5-Amino-Pyrazole Based Inhibitor

Chain A, P38 Alpha Kinase Complexed With A Pyrazolo-Triazine Based Inhibitor

Chain A, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With 5-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2- Methylphenyl)-2-thiophenecarboxamide

Chain B, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With 5-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2- Methylphenyl)-2-thiophenecarboxamide

Chain C, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With 5-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2- Methylphenyl)-2-thiophenecarboxamide

Chain D, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With 5-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2- Methylphenyl)-2-thiophenecarboxamide

Chain A, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With 2-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2- Methylphenyl)-1,3-thiazole-5-carboxamide

Chain B, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With 2-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2- Methylphenyl)-1,3-thiazole-5-carboxamide

Chain A, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With Ethyl 6-((5-(cyclopropylcarbamoyl)-2-methylphenyl) Carbamoyl)-1h-indole-1-carboxylate

Chain B, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With Ethyl 6-((5-(cyclopropylcarbamoyl)-2-methylphenyl) Carbamoyl)-1h-indole-1-carboxylate

Chain C, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With Ethyl 6-((5-(cyclopropylcarbamoyl)-2-methylphenyl) Carbamoyl)-1h-indole-1-carboxylate

Chain D, Crystal Structure Of Mitogen-activated Protein Kinase 14 (p38-h5) Complex With Ethyl 6-((5-(cyclopropylcarbamoyl)-2-methylphenyl) Carbamoyl)-1h-indole-1-carboxylate

ChainA, Crystal Structure Of P38 Kinase In Complex With A Pyrrole-2- Carboxamide Inhibitor

ChainA, P38 Mitogen-Activated Kinase In Complex With 4-Azaindole Inhibitor

Chain A, P38 Kinase Crystal Structure In Complex With 6-(2,4- Difluoro-Phenoxy)-2-((S)-2-Methanesulfonyl-1-Methyl- Ethylamino)-8-Methyl-8h-Pyrido[2,3-D]pyrimidin

Chain A, P38 Kinase Crystal Structure In Complex With 6-(2,4- Difluoro-Phenoxy)-2-((R)-2-Methanesulfonyl-1-Methyl- Ethylamino)-8-Methyl-8h-Pyrido[2,3-D]pyrimidin-7-One

Chain A, P38 Kinase Crystal Structure In Complex With 6-(2,4- Difluoro-Phenoxy)-2-Isopropylamino-8-Methyl-8h-Pyrido[2,3- D]pyrimidin-7-One

Chain A, P38 Kinase Crystal Structure In Complex With 8-Methyl-6-Phenoxy-2- (Tetrahydro-Pyran-4-Ylamino)-8h-Pyrido[2,3-D]pyrimidin-7-One

Chain A, P38 Kinase Crystal Structure In Complex With 6-(2,4-Difluoro-Phenoxy)- 8-Methyl-2-((R)-1-Methyl-2-Tetrazol-2-Yl-Ethylamino)-8h-Pyrido[2,3- D]pyrimidin-7-One

Chain A, P38 Kinase Crystal Structure In Complex With 4-(5-Methyl-3-Phenyl- Isoxazol-4-Yl)-Pyrimidin-2-Ylamine

Chain A, P38 Kinase Crystal Structure In Complex With 6-(2,4-Difluoro-Phenoxy)- 8-Methyl-2-((S)-1-Methyl-2-Tetrazol-2-Yl-Ethylamino)-8h-Pyrido[2,3- D]pyrimidin-7-One

Chain A, P38 Kinase Crystal Structure In Complex With 3-(2,6- Dichloro-Phenyl)-7-[4-(2-Diethylamino-Ethoxy)-Phenylamino]- 1-Methyl-3,4-Dihydro-1h-Pyrimido[4,5-D]pyrimidin-2-One

ChainA, Structure Of Human P38alpha With N-[4-Methyl-3-(6-{[2-(1- Methylpyrrolidin-2-Yl)ethyl]amino}pyridine-3-Amido)phenyl]- 2-(Morpholin-4-Yl)pyridine-4-Carboxamide

Chain A, The structure of p38 alpha in complex with a triazol inhibitor

ChainA, Human P38alpha Mapk In Complex With A Novel And Selective Small Molecule Inhibitor

Chain A, Human P38 Alpha Mapk In Complex With A Novel And Selective Small Molecule Inhibitor

Chain A, Human P38 Alpha Mitogen-activated Kinase In Complex With Sb239063

Chain A, Structure Of Human P38amapk-arylpyridazinylpyridine Fragment Complex Used In Inhibitor Discovery

Chain A, Dual Binding Mode Of Pyridinylimidazole To Map Kinase P38

Chain A, The Complex Structure Of The Map Kinase P38COMPOUND 14B

ChainA, Mutant Mus Musculus P38 Kinase Domain In Complex With Inhibitor Pg- 874743

Chain A, Mutated Map Kinase P38 (mus Musculus) In Complex With Inhbitor Pg- 895449

ChainA, Crystal structure of p38 complex with 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea

Chain A, Structure Of Map Kinase P38 In Complex With A 1-O-Tolyl-1,2, 3-Triazole-4-Carboxamide

ChainA, Crystal Structure Analysis Of Inactive P38 Kinase Domain In Complex With A Monocyclic Pyrazolone Inhibitor

ChainA, Mutagenesis Of P38 Map Kinase Establishes Key Roles Of Phe169 In Function And Structural Dynamics And Reveals A Novel Dfg-Out State

Chain A, Conformational Plasticity Of P38 Map Kinase Dfg Motif Mutants In Response To Inhibitor Binding

ChainX, Crystal Structure Of Y323f Inactive Mutant Of P38alpha Map Kinase

ChainA, Structure Of Dead Kinase Mapk14 With Bound The Kim Domain Of Mkk6

ChainA, Human p38 alpha MAPK in complex with a pyridazine based inhibitor

ChainA, Covalent Inhibitor 4b Bound To The Lipid Pocket Of P38alpha Mutant S252c

ChainA, Covalent Inhibitor 4a Bound To The Lipid Pocket Of P38alpha Mutant S251c

ChainA, The Structure Of P38 Alpha In Complex With A Dihydroquinolinone

Chain A, The Structure Of P38alpha In Complex With An Arylpyridazinone

Chain A, The Structure Of P38alpha In Complex With A Dihydroquinazolinone

ChainA, Conformational Plasticity Of P38 Map Kinase Dfg Motif Mutants In Response To Inhibitor Binding

ChainA, Crystal structure of phosphorylated P38 alpha in complex with DP802

ChainA, Crystal structure of human p38alpha complexed with a MAPK docking peptide

ChainA, Mutagenesis Of P38 Map Kinase Eshtablishes Key Roles Of Phe169 In Function And Structural Dynamics And Reveals A Novel Dfg-Out State

Chain A, Conformational Plasticity Of P38 Map Kinase Dfg-Motif Mutants In Response To Inhibitor Binding

ChainX, Mitogen Activated Protein Kinase P38alpha (D176a) Activating Mutant

Chain A, Conformational Plasticity Of P38 Map Kinase Dfg Mutants In Response To Inhibitor Binding

ChainA, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide]

ChainA, Crystal Structure Of P38 Kinase In Complex With A Biphenyl Amide Inhibitor

ChainA, Crystal Structure Of P38 Kinase In Complex With A Biaryl Amide Inhibitor

Chain A, Crystal Structure Of P38 Kinase In Complex With A Biaryl Amide Inhibitor

ChainA, Crystal structure of p38 alpha MAP kinase in complex with a novel isoform selective drug candidate

ChainA, Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b]pyridazine-based p38 MAP Kinase Inhibitors

Chain A, Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b]pyridazine-based p38 MAP Kinase Inhibitors

ChainX, Mitogen Activated Protein Kinase P38alpha (d176a+f327l) Activating Mutant

ChainX, Mitogen Activated Protein Kinase P38alpha (D176a+f327s) Activating Mutant Form-A

Chain X, Mitogen Activated Protein Kinase P38alpha (D176a+f327s) Activating Mutant Form-B

Chain A, Crystal structure of p38 in complex with a biphenylamide inhibitor

Chain A, Human P38 Map Kinase In Complex With An Indole Derivative

Chain A, Human P38 Map Kinase In Complex With A Benzylpiperazin- Pyrrol

Chain A, Human P38 Map Kinase In Complex With An Imidazo-Pyridine

Chain A, Structure Of Inactive Human P38 Map Kinase In Complex With A Thiazole-Urea

ChainA, P38a Map Kinase Def-pocket Penta Mutant (m194a, L195a, H228a, I229a, Y258a)

ERPTFYRQELNKTIWEVPERYQ LSPVGSGAYGSVC+++D K+G ++AVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPA SLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYN TVDIWSVGCIMAELLTGRTLFPGTDHI+QL+ I+RL GTP A ++ ++ S  ARNYI SL QMPK NFA+VFIGANPLAVDLLEKMLVLD+DKRITA++ALAH YF+QYHDPDDEP ++PYDQSFESR L I+EWK LTY+EV SF  PP D

R  FYRQELNKT+WEVP+R Q L PVGSGAYGSVC+A+D +   +VAVKKLSRPFQS+IHA+RTYRELRLLKH+KHENVIGLLDVFTPA S+E+F++VYLVT LMGADLNNIVKCQ L+D+HVQFL+YQ+LRGLKYIHSA IIHRDLKPSN+AVNEDCEL+ILDFGLAR  D+EMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELL G+ LFPG+D+IDQLK I+ +VGTP  E+L KISSE AR YIQSL  MP+ + +++F GANPLA+DLL +MLVLDSD+R++AA+ALAHAYF+QYHDP+DEP A+PYD+S E+++  ++EWK LTY EV+SF P

ChainA, Crystal Structure Of Human Mitogen Activated Protein Kinase 11 (p38 Beta) In Complex With Nilotinib

R  FYRQELNKT+WEVP+R Q L PVGSGAYGSVC+A+D +   +VAVKKLSRPFQS+IHA+RTYRELRLLKH+KHENVIGLLDVFTPA S+E+F++VYLVT LMGADLNNIVKCQ L+D+HVQFL+YQ+LRGLKYIHSA IIHRDLKPSN+AVNED EL+ILDFGLAR  D+EMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELL G+ LFPG+D+IDQLK I+ +VGTP  E+L KISSE AR YIQSL  MP+ + +++F GANPLA+DLL +MLVLDSD+R++AA+ALAHAYF+QYHDP+DEP A+PYD+S E+++  ++EWK LTY EV+SF

ChainA, The Structure Of P38beta C162s In Complex With A Dihydroquinazolinone

Chain B, The Structure Of P38beta C162s In Complex With A Dihydroquinazolinone

R  FYRQELNKT+WEVP+R Q L PVGSGAYGSVC+A+D +   +VAVKKLSRPFQS+IHA+RTYRELRLLKH+KHENVIGLLDVFTPA S+E+F++VYLVT LMGADLNNIVK Q L+D+HVQFL+YQ+LRGLKYIHSA IIHRDLKPSN+AVNED EL+ILDFGLAR  D+EMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELL G+ LFPG+D+IDQLK I+ +VGTP  E+L KISSE AR YIQSL  MP+ + +++F GANPLA+DLL +MLVLDSD+R++AA+ALAHAYF+QYHDP+DEP A+PYD+S E+++  ++EWK LTY EV+SF

ChainA, The Structure Of P38beta C119s, C162s In Complex With A Dihydroquinazolinone Inhibitor

Chain B, The Structure Of P38beta C119s, C162s In Complex With A Dihydroquinazolinone Inhibitor

R  FYRQE+ KT WEV   Y++L PVGSGAYG+VC+A D +TG +VA+KKL RPFQS + AKR YRELRLLKHM+HENVIGLLDVFTP  +L++F D YLV   MG DL  ++K +KL +D +QFL+YQ+L+GL+YIH+A IIHRDLKP NLAVNEDCELKILDFGLAR  D EM G V TRWYRAPE++LNWM Y QTVDIWSVGCIMAE++TG+TLF G+DH+DQLK I+++ GTP AE ++++ S+ A+NY++ L ++ K +FA++   A+PLAV+LLEKMLVLD+++R+TA +ALAH YF   HD +DEP    YD SF+  D  +DEWK +TY EV+SF PP

+  FY+Q++NKT WE+P+ Y + + VGSGAYGSVC+A D ++G +VA+KKLSRPFQS I AKR YREL LLKHM+HENVIGLLDVFTPA SL  F D YLV   M  DL  I+   K +++ +Q+L+YQ+L+GLKYIHSA ++HRDLKP NLAVNEDCELKILDFGLARH D EMTGYV TRWYRAPE++L+WMHYNQTVDIWSVGCIMAE+LTG+TLF G D++DQL  IL++ G PG E ++K++ ++A++YIQSL Q P+ +F  +F  A+P A DLLEKML LD DKR+TAAQAL H +F  + DP++E  A  P+D S E   L +DEWK   Y E+++F P

+  FY+Q++NKT WE+P+ Y + + VGSGAYGSVC+A D ++G +VA+KKLSRPFQS I AKR YREL LLKHM+HENVIGLLDVFTPA SL  F D YLV   M  DL  I+  +  +++ +Q+L+YQ+L+GLKYIHSA ++HRDLKP NLAVNEDCELKILDFGLARH D EMTGYV TRWYRAPE++L+WMHYNQTVDIWSVGCIMAE+LTG+TLF G D++DQL  IL++ G PG E ++K++ ++A++YIQSL Q P+ +F  +F  A+P A DLLEKML LD DKR+TAAQAL H +F  + DP++E  A  P+D S E   L +DEWK   Y E+++F P

+  FY+Q++NKT WE+P+ Y + + VGSGAYGSVC+A D ++G +VA+KKLSRPFQS I AKR YREL LLKHM+HENVIGLLDVFTPA SL  F D YLV   M  DL  I+  +  +++ +Q+L+YQ+L+GLKYIHSA ++HRDLKP NLAVNEDCELKILDFGLARH D EM G V TRWYRAPE++L+WMHYNQTVDIWSVGCIMAE+LTG+TLF G D++DQL  IL++ G PG E ++K++ ++A++YIQSL Q P+ +F  +F  A+P A DLLEKML LD DKR+TAAQAL H +F  + DP++E  A  P+D S E   L +DEWK   Y E+++F P

FY  ++  + + V +RYQ L P+GSGA G VCAAFDT  G  VAVKKLSRPFQ+  HAKR YREL LLK + H+N+I LL+VFTP ++LEEF DVYLV  LM A+L  ++  + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T+  MT YV TR+YRAPE++L  M Y + VDIWSVGCIM EL+ G  +F GTDHIDQ   ++  +GTP AE +  +   + RNY+++    P + F  +F                  A DLL KMLV+D DKRI+  +AL H Y   ++DP +     P  YD   E R+  I+EWK L Y EV+

FY  E+  + + V +RYQ L P+GSGA G VCAAFDT  G  VAVKKLSRPFQ+  HAKR YREL LLK + H+N+I LL+VFTP ++LEEF DVYLV  LM A+L  ++   +L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T+  MT YV TR+YRAPE++L  M Y   VDIWSVGCIM EL+ G  +F GTDHIDQ   ++  +GTP AE +  +   + RNY+++  + P + F  +F                  A DLL KMLV+D DKRI+  +AL H Y   ++DP +     P  YD   E R+  I+EWK L Y EV+ +

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVYLVTHLMGADL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N   +LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

ChainA, Structure Of Penta Mutant Human Erk2 Map Kinase Complexed With A Specific Inhibitor Of Human P38 Map Kinase

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L+ +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+

ChainA, Crystal Structure Of A Cysteine-deficient Mutant M2 In Map Kinase Jnk1

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+

ChainA, Crystal Structure Of A Cysteine-deficient Mutant M1 In Map Kinase Jnk1

ChainA, Structural Basis For The Selective Inhibition Of Jnk1 By The Scaffolding Protein Jip1 And Sp600125

Chain A, Structural Basis For The Selective Inhibition Of Jnk1 By The Scaffolding Protein Jip1 And Sp600125

Chain A, Crystal Structure Of Jnk1beta-jip In Complex With An Azaquinolone Inhbitor

Chain A, Crystal Structure Of Jnk1 In Complex With Jip1 Peptide And 7-fluoro-3- [4-(2-hydroxy-ethanesulfonyl)-benzyl]-4-oxo-1-phenyl-1,4-dihydro- Quinoline-2-carboxylic Acid Methyl Ester

Chain A, Crystal Structure Of Jnk1 In Complex With Jip1 Peptide And 4-(4- Indazol-1-yl-pyrimidin-2-ylamino)-cyclohexan

Chain A, Crystal Structure Of Jnk1 In Complex With Jip1 Peptide And 4-{4-[4-(3- Methanesulfonyl-propoxy)-indazol-1-yl]-pyrimidin-2-ylamino}- Cyclohexan

Chain A, Crystal Structure Of Jnk1 In Complex With Jip1 Peptide And 4-{4-[4-(4- Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}- Cyclohexan

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L+ +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  D  LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+

ChainA, Crystal Structure Of A Cysteine-deficient Mutant M5 In Map Kinase Jnk1

ChainA, Crystal Structure Of A Cysteine-deficient Mutant M3 In Map Kinase Jnk1

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+  

ChainA, Linear Binding Motifs For Jnk And For Calcineurin Antagonistically Control The Nuclear Shuttling Of Nfat4

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+  +

ChainE, Crystal Structure Of Jnk In Complex With A Regulator Protein

Chain A, Crystal Structure Of Jnk In Complex With A Regulator Protein

Chain C, Crystal Structure Of Jnk In Complex With A Regulator Protein

Chain F, Crystal Structure Of Jnk In Complex With A Regulator Protein

Y  E+  T + +  RY NL P+GSGA G VCAA+DT T   VA+KKLSRPFQ++ HAKR YRE +L+K + H+N+IGLL+ FTP R+LEEF DVYLV  LM A+L  +++   L  D + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++ G  LFPGTDHIDQ   I+  +GTP    ++++   + RNY+++  +    +F  +F  G  P             A +LL KMLV+D ++RI+  +AL H Y   ++D +  D P  +PYD S + R+  +++WK L Y+EV+ +

ChainA, The Crystal Structure Of Jnk From Drosophila Melanogaster Reveals An Evolutionarily Conserved Topology With That Of Mammalian Jnk Proteins.

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   M  +V TR+YRAPE++L  M Y + VDIWSVGCIM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L+ +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  D  LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVG IM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+

FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+I LL+VFTP ++LEEF DVYLV  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + RNY+++  +   + F  +F  +        N L    A DLL KMLV+D  KRI+   AL H Y   ++DP +     P  YD+  + R+  I+EWK L Y EV++

ChainA, Crystal Structure Of Jnk3 In Complex With An Imidazole-pyrimidine Inhibitor

Chain A, The Crystal Structure Of Jnk3 In Complex With A Phenantroline Inhibitor

Chain A, The Structure Of Jnk3 In Complex With A Dihydroanthrapyrazole Inhibitor

Chain A, The Structure Of Jnk3 In Complex With An Imidazole-pyrimidine Inhibitor

ChainA, Jnk2/3 In Complex With 3-(4-{[(2-chlorophenyl)carbamoyl]amino}-1h- Pyrazol-1-yl)-n-(2-methylpyridin-4-yl)benzamide

Chain A, Jnk2/3 In Complex With N-(2-methylpyridin-4-yl)-3-{4- [(phenylcarbamoyl)amino]-1h-pyrazol-1-yl}benzamide

Chain A, Jnk2/3 In Complex With 3-(4-{[(4-fluorophenyl)carbamoyl]amino}-1h- Pyrazol-1-yl)-n-(2-methylpyridin-4-yl)benzamide

Chain A, Jnk2/3 In Complex With 3-(4-{[(4-methylphenyl)carbamoyl]amino}-1h- Pyrazol-1-yl)-n-(2-methylpyridin-4-yl)benzamide

Chain A, Pyridopyrimidinone Derivatives As Potent And Selective C-jun N- Terminal Kinase (jnk) Inhibitors

ChainA, Design And Synthesis Of Disubstituted Thiophene And Thiazole Based Inhibitors Of Jnk For The Treatment Of Neurodegenerative Diseases

Chain A, Highly Selective C-Jun N-Terminal Kinase (Jnk) 2 And 3 Inhibitors With In Vitro Cns-Like Pharmacokinetic Properties

ChainA, Design And Synthesis Of A Novel, Orally Efficacious Tri-Substituted Thiophene Based Jnk Inhibitor

Chain A, Design And Synthesis Of Brain Penetrant Selective Jnk Inhibitors With Improved Pharmacokinetic Properties For The Prevention Of Neurodegeneration

ChainA, Crystal Structure Of Human Jnk3 Complexed With N-{3-cyano-6-[3-(1- Piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}- 1-naphthalenecarboxamide

Chain A, Crystal Structure Of Human Jnk3 Complexed With N-(3-cyano-4,5,6,7- Tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide

Chain A, Crystal Structure Of Human Jnk3 Complexed With An Isoquinolone Inhibitor

Chain A, Crystal Structure Of Human Jnk3 Complexed With N-(3-methyl-4-(3-(2- (methylamino)pyrimidin-4-yl)pyridin-2-yloxy)naphthalen-1-yl)-1h- Benzo[d]imidazol-2-amine

Chain A, Crystal Structure Of Human Jnk3 Complexed With A 1-Aryl-3,4- Dihydroisoquinoline Inhibitor

Chain A, Discovery Of Potent And Selective Covalent Inhibitors Of Jnk

Chain B, Discovery Of Potent And Selective Covalent Inhibitors Of Jnk

Chain A, Crystal Structure Of Human Jnk3 In Complex With A Benzenesulfonamide Inhibitor.

ChainA, Crystal Structure Of Jnk3 Bound To N-benzyl-4-(4-(3-chlorophenyl)-1h- Pyrazol-3-yl)-1h-pyrrole-2-carboxamide

Chain A, Synthesis And Sar Of Aminopyrimidines As Novel C-jun N-terminal Kinase (jnk) Inhibitors

Chain A, Irak-4 Inhibitors (part Ii)- A Structure Based Assessment Of Imidazo[1,2 A]pyridine Binding

Chain X, Jnk-3 Bound To (Z)-5-Fluoro-1-((6-Fluoro-4h-Benzo[d][1,3]dioxin-8-Yl) Methyl)-3-(Hydroxyimino)indolin-2-One

Chain A, JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-phenylindolin-2-one

Chain X, JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-styrylindolin-2-one

ChainA, Design And Synthesis Of Highly Potent And Isoform Selective Jnk3 Inhibitors: Sar Studies On Aminopyrazole Derivatives

ChainA, The C-Jun N-Terminal Kinase (Jnk3s) Complexed With Mgamp-Pnp

FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+I LL+VFTP ++LEEF DVYLV  LM A+L  +++  +L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + RNY+++  +   + F  +F  +        N L    A DLL KMLV+D  KRI+   AL H Y   ++DP +     P  YD+  + R+  I+EWK L Y EV++

ChainA, Crystal Structure Of Jnk3 Complexed With Cc-359, A Jnk Inhibitor For The Prevention Of Ischemia-Reperfusion Injury

Chain A, Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitor

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++KCQ L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKILDFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

ChainA, Crystal Structure Of A Double Mutant Rat Erk2 Complexed With A Type Ii Quinazoline Inhibitor

Chain A, A Double Mutant Rat Erk2 In Complex With A Pyrazolo[3,4-d]pyrimidine Inhibitor

Chain B, A Double Mutant Rat Erk2 In Complex With A Pyrazolo[3,4-d]pyrimidine Inhibitor

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y AQY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

ChainA, Crystal Structure Of Human Erk2 Complexed With A Mapk Docking Peptide

Chain A, Crystal Structure Of Human Erk2 Complexed With A Mapk Docking Peptide

Chain D, Crystal Structure Of Human Erk2 Complexed With A Mapk Docking Peptide

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR    D + TG    YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

ChainA, Structure Of The Complex Between Erk2 Phosphomimetic Mutant And Pea-15

Chain B, Structure Of The Complex Between Erk2 Phosphomimetic Mutant And Pea-15

Chain C, Structure Of The Complex Between Erk2 Phosphomimetic Mutant And Pea-15

Chain D, Structure Of The Complex Between Erk2 Phosphomimetic Mutant And Pea-15

 FY  E+  + + V +RYQNL P+GSGA G V AA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L+ +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  D  LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVG IM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+

ChainA, Crystal Structure Of A Cysteine-deficient Mutant M7 In Map Kinase Jnk1

FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+I LL+VFTP ++LEEF DVYLV  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  D  LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + RNY+++  +   + F  +F  +        N L    A DLL KMLV+D  KRI+   AL H Y   ++DP +     P  YD+  + R+  I+EWK L Y EV++

ChainA, Crystal Structure Of Jnk3 With Indazole Inhibitor, Sr-3737

ChainA, C-jun N-terminal Kinase 3 With 3,5-disubstituted Quinoline Inhibitor

Chain B, C-jun N-terminal Kinase 3 With 3,5-disubstituted Quinoline Inhibitor

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT  V TR+YRAPE++L  M Y + VDIWSVGCIM E++ G  LFPGTDHIDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+     P

ChainA, Structural And Functional Analysis Of Quercetagetin, A Natural Jnk1 Inhibitor

++V  RY  L  +G GAYG V +A+D     RVA+KK+S PF+   + +RT RE+++L   +HENVIG+ D+   A +LE   DVY+V  LM  DL  ++K Q+L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D E      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+QSL    K+ +A +F  ++  A+DLL++ML  + +KRIT  +ALAH Y  QY+DP DEPVA +P+  + E  DL  +  K L + E   F P  L+

ChainA, Structure Of Human Erk1 In Complex With Sch772984 Revealing A Novel Inhibitor-induced Binding Pocket

Chain B, Structure Of Human Erk1 In Complex With Sch772984 Revealing A Novel Inhibitor-induced Binding Pocket

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

Chain A, Crystal Structure Of Mitogen-activated Protein Kinase 1 Wterk2 At 1.45a

ChainA, Structure Of Human Erk2 In Complex With Sch772984 Revealing A Novel Inhibitor-induced Binding Pocket

Chain A, Structure Of Erk2 In Complex With Vtx-11e, 4-{2-[(2-chloro-4- Fluorophenyl)amino]-5-methylpyrimidin-4-yl}-n-[(1s)-1-(3- Chlorophenyl)-2-hydroxyethyl]-1h-pyrrole-2-carboxamide

ChainA, Crystal Structure Of Erk-2 With Hypothemycin Covalently Bound

Chain B, Crystal Structure Of Erk-2 With Hypothemycin Covalently Bound

ChainC, Structure Of Non-phosphorylated Erk2 Bound To The Pea-15 Death Effector Domain

Chain A, Structure Of Non-phosphorylated Erk2 Bound To The Pea-15 Death Effector Domain

ChainA, Crystal Structure Of Erk2 In Complex With N-cyclohexyl-9h-purin-6- Amine

Chain B, Crystal Structure Of Erk2 In Complex With N-cyclohexyl-9h-purin-6- Amine

Chain A, Crystal Structure Of Erk2 In Complex With 2-(1h-pyrazol-4-yl)-5h- Pyrrolo[2,3-b]pyrazine

Chain B, Crystal Structure Of Erk2 In Complex With 2-(1h-pyrazol-4-yl)-5h- Pyrrolo[2,3-b]pyrazine

Chain A, Crystal Structure Of Erk2 In Complex With 2-(1h-pyrazol-4-yl)-7- (pyridin-3-yl)-5h-pyrrolo[2,3-b]pyrazine

Chain B, Crystal Structure Of Erk2 In Complex With 2-(1h-pyrazol-4-yl)-7- (pyridin-3-yl)-5h-pyrrolo[2,3-b]pyrazine

Chain A, Crystal Structure Of Erk2 In Complex With 7-(1-propyl-1h-pyrazol-4- Yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine

ChainA, Erk2 Complexed With N-benzylpyridone Tetrahydroazaindazole

Chain A, Tetrahydropyrrolo-diazepenones As Inhibitors Of Erk2 Kinase

ChainB, Crystal Structure Of Erk2 Complex With Kim Peptide Derived From Mkp3

Chain A, Crystal Structure Of Erk2 Complex With Kim Peptide Derived From Mkp3

ChainA, The Structure Of Erk2 In Complex With A Small Molecule Inhibitor

ChainA, Crystal Structure Of Human Erk2 Complexed With A Pyrazolopyridazine Derivative

Chain A, Crystal Structure Of Erk2 Complexed With Allosteric And Atp- Competitive Inhibitors.

ChainA, Crystal Structure Of A Designed Selected Ankyrin Repeat Protein In Complex With The Map Kinase Erk2

ChainA, Discovery Of Novel, Dual Mechanism Erk Inhibitors By Affinity Selection Screening Of An Inactive Kinase State

Chain A, Dissecting Therapeutic Resistance To Erk Inhibition Rat Wild Type Sch772984 In Complex With (3r)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl) Phenyl]piperazin-1-yl}ethyl)-n-[3-(pyridin-4-yl)-2h-indazol-5- Yl]pyrrolidine-3-carboxamide

ChainA, Unphosphorylated Mitogen Activated Protein Kinase Erk2 In Complex With (4-{[5-Carbamoyl-4-(3-Methylanilino)pyrimidin 2-Yl]amino}phenyl)acetic Acid

Chain A, Discovery of 1-1H-Pyrazolo 4,3-c pyridine-6-yl urea Inhibitors of Extracellular Signal Regulated Kinase ERK for the Treatment of Cancers

Chain A, Discovery Of Mli-2, An Orally Available And Selective Lrrk2 Inhibitor That Reduces Brain Kinase Activity

ChainA, Discovery Of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Inhibitors Of Erk2

ChainA, Crystal Structure Of Erk2 In Complex With N,n-dimethyl-4-(4- Phenyl-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide

Chain A, Crystal Structure Of Erk2 In Complex With N-benzyl-4-(4-(3- Chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide

Chain A, Crystal Structure Of Erk2 In Complex With (s)-n-(1-(3-chloro-4- Fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)- 1h-pyrrole-2-carboxamide

Chain A, Crystal structure of ERK2 bound to (S)-N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-1H-pyrrole-2-carboxamide

Chain A, Crystal structure of ERK2 bound to (S)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-2-carboxamide

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG  D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR    D + TG+    VATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

ChainA, Crystal Structure Of A Designed Selected Ankyrin Repeat Protein In Complex With The Phosphorylated Map Kinase Erk2

Chain C, Crystal Structure Of A Designed Selected Ankyrin Repeat Protein In Complex With The Phosphorylated Map Kinase Erk2

ChainA, Structure Of Dually Phosphorylated Erk2 Bound To The Pea-15 Death Effector Domain

Chain C, Structure Of Dually Phosphorylated Erk2 Bound To The Pea-15 Death Effector Domain

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VD+WSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+

Chain B, Crystal Structure Of Jnk1 Bound To A Mkk7 Docking Motif

Chain C, Crystal Structure Of Jnk1 Bound To A Mkk7 Docking Motif

Chain D, Crystal Structure Of Jnk1 Bound To A Mkk7 Docking Motif

ChainA, Structure Of Human Jnk1 In Complex With Sch772984 And The Amppnp- Hydrolysed Triphosphate Revealing The Second Type-i Binding Mode

ChainA, Jnk1 Complexed With A Bis-Anilino-Pyrrolopyrimidine Inhibitor.

Chain A, Human Jnk1alpha Kinase With 4-phenyl-7-azaindole Ikk2 Inhibitor.

++V  RY  L  +G GAYG V +A+D     RVA+KK+S PF+   + +RT RE+++L   +HENVIG+ D+   A +LE   DVY+V  LM  DL  ++K Q+L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D E      +T  VATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+QSL    K+ +A +F  ++  A+DLL++ML  + +KRIT  +ALAH Y  QY+DP DEPVA +P+  + E  DL  +  K L + E   F P  L+

ChainA, Structural Dissection Of Human Mitogen-Activated Kinase Erk1

Chain B, Structural Dissection Of Human Mitogen-Activated Kinase Erk1

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VD+WSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+  

ChainB, Crystal Structure Of Darpin-darpin Rigid Fusion, Variant Dd_d12_10_47 In Complex With Jnk1a1 And Jip1 Peptide

Chain B, Crystal structure of DARPin-DARPin rigid fusion, variant DD_232_11_D12 in complex JNK1a1 and JIP1 peptide

Chain E, Crystal structure of DARPin-DARPin rigid fusion, variant DD_232_11_D12 in complex JNK1a1 and JIP1 peptide

Chain H, Crystal structure of DARPin-DARPin rigid fusion, variant DD_232_11_D12 in complex JNK1a1 and JIP1 peptide

Chain B, Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_10_47 in complex JNK1a1 and JIP1 peptide

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VD+WSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+ +

FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+I LL+VFTP ++LEEF DVYLV  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  D  LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + RNY+++  +   + F  +F  +        N L    A DLL KMLV+D  KRI+   AL H Y   ++DP      D        R+  I+EWK L Y EV++

+++V  RY NLS +G GAYG VC+A+D     RVA++K+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

ChainA, Coordinates Of Rat Map Kinase Erk2 With An Arginine Mutation At Position 52

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + + T RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N   +LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++D + + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

ChainA, Crystal Structure Of Erk2 In Complex With An Inhibitor 14k

Chain B, Crystal Structure Of Erk2 In Complex With An Inhibitor 14k

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N  C+LKI DF LAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

ChainA, Dissecting Therapeutic Resistance to ERK Inhibition Rat Mutant SCH772984 in complex with (3R)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-N-[3-(pyridin-4-yl)-2H-indazol-5-yl]pyrrolidine-3-carboxamide

Chain A, Crystal Structure Of Erks In Complex With 5-chlorobenzo[d]oxazol-2- Amine

Chain B, Crystal Structure Of Erks In Complex With 5-chlorobenzo[d]oxazol-2- Amine

Chain A, Crystal Structure Of Erk2 In Complex With (s)-2-((9h-purin-6-yl) Amino)-3-phenylpropan-1-ol

Chain B, Crystal Structure Of Erk2 In Complex With (s)-2-((9h-purin-6-yl) Amino)-3-phenylpropan-1-ol

Chain A, Crystal Structure Of Erk2 In Complex With 5h-pyrrolo[2,3-b]pyrazine

Chain B, Crystal Structure Of Erk2 In Complex With 5h-pyrrolo[2,3-b]pyrazine

Chain A, Crystal Structure Of Erk2 In Complex With 7-(1-benzyl-1h-pyrazol-4- Yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine

Chain B, Crystal Structure Of Erk2 In Complex With 7-(1-benzyl-1h-pyrazol-4- Yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine

ChainA, In-gel Activity-based Protein Profiling Of A Clickable Covalent Erk 1/2 Inhibitor

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N   +LKI DFGLAR  D +      +T YVATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L    +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y AQY+DP DEP+A+ P+    E  DL  ++ K L ++E   F P

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   M   V TR+YRAPE++L  M Y + VDIWSVGCIM E++  + LFPG D+IDQ   ++  +GTP    +KK+   + RNY+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+  

Chain A, Crystal Structure Of Jnk1-Alpha1 Isoform Complex With A Biaryl Tetrazol (A-82118)

Chain B, Crystal Structure Of Jnk1-Alpha1 Isoform Complex With A Biaryl Tetrazol (A-82118)

+++V  RY NLS +G GAYG VC+A+D     RVA+KK+S PF+   + +RT RE+++L   +HEN+IG+ D+   A ++E+  DVY+V  LM  DL  ++K Q L++DH+ + +YQILRGLKYIHSA+++HRDLKPSNL +N   +LKI DFGLAR  D +      +T  VATRWYRAPEIMLN   Y +++DIWSVGCI+AE+L+ R +FPG  ++DQL  IL ++G+P  E L  I +  ARNY+ SL    K+ +  +F  A+  A+DLL+KML  +  KRI   QALAH Y  QY+DP DEP+A+ P+    E  DL  ++ K L ++E   F

ChainA, Crystal Structure At Room Temperature Of Erk2 In Complex With An Inhibitor

 FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+IGLL+VFTP +SLEEF DVY+V  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  DC LKILDFGLAR   T   M   V TR+YRAPE++L  M Y + VD+WSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + R Y+++  +    +F  +F           N L    A DLL KMLV+D+ KRI+  +AL H Y   ++DP +     P   D+  + R+  I+EWK L Y EV+  

Chain A, Selective Aminopyridine-Based C-Jun N-Terminal Kinase Inhibitors With Cellular Activity

Chain B, Selective Aminopyridine-Based C-Jun N-Terminal Kinase Inhibitors With Cellular Activity

Chain A, Discovery Of Potent, Highly Selective, And Orally Bioavailable Pyridine Carboxamide C-Jun Nh2-Terminal Kinase Inhibitors

Chain B, Discovery Of Potent, Highly Selective, And Orally Bioavailable Pyridine Carboxamide C-Jun Nh2-Terminal Kinase Inhibitors

FY  E+  + + V +RYQNL P+GSGA G VCAA+D      VA+KKLSRPFQ+  HAKR YREL L+K + H+N+I LL+VFTP ++LEEF DVYLV  LM A+L  +++ + L  + + +L+YQ+L G+K++HSA IIHRDLKPSN+ V  D  LKILDFGLAR   T   MT YV TR+YRAPE++L  M Y + VDIWSVGCIM E++  + LFPG D+IDQ   ++  +GTP  E +KK+   + RNY+++  +   + F  +F  +        N L    A DLL KMLV+D  KRI+   AL H Y   ++               + R+  I+EWK L Y EV++

ChainA, Crystal Structure Of Jnk3 With Amino-Pyrazole Inhibitor, Sr- 3451

+ Y+ +  +G+GAYG V +A    TG +VA+KK+   F  + +AKRT REL++LKH KH+N+I + D+  P     EF  VY+V  LM +DL+ I+   Q LT +HV++ +YQ+LRGLKY+HSA +IHRDLKPSNL VNE+CELKI DFG+AR            MT YVATRWYRAPE+ML+   Y Q +D+WSVGCI  E+L  R LFPG +++ QL+LI+ ++GTP   +++ + +E  R YIQSL     + +  V+ GA+  A+ LL +ML  +   RI+AA AL H + A+YHDPDDEP  A P+D +F+   L  +  K     E+  F

ChainA, Mitogen Activated Protein Kinase 7 In Complex With Inhibitor

+V + Y+ +  +G+GAYG V +A    TG +VA+KK+   F  + +AKRT REL++LKH KH+N+I + D+  P     EF  VY+V  LM +DL+ I+   Q LT +HV++ +YQ+LRGLKY+HSA +IHRDLKPSNL VNE+CELKI DFG+AR            MT YVATRWYRAPE+ML+   Y Q +D+WSVGCI  E+L  R LFPG +++ QL+LI+ ++GTP   +++ + +E  R YIQSL     + +  V+ GA+  A+ LL +ML  +   RI+AA AL H + A+YHDPDDEP  A P+D +F+   L  +  K     E+  F

++V + Y+ +  +G+GAYG V +A    TG +VA+KK+   F  + +AKRT REL++LKH KH+N+I + D+  P     EF  VY+V  LM +DL+ I+   Q LT +HV++ +YQ+LRGLKY+HSA +IHRDLKPSNL VNE+CELKI DFG+AR            MT YVATRWYRAPE+ML+   Y Q +D+WSVGCI  E+L  R LFPG +++ QL+LI+ ++GTP   +++ + +E  R YIQSL     + +  V+ GA+  A+ LL +ML  +   RI+AA AL H + A+YHDPDDEP  A P+D +F+   L  +  K     E+  F

ChainA, Crystal Structure Of The Erk5 Kinase Domain In Complex With An Mkk5 Binding Fragment

Chain D, Crystal Structure Of The Erk5 Kinase Domain In Complex With An Mkk5 Binding Fragment

F +  +   I+EV  +Y+  + P+G GAYG VC+A +++T   VA+KK++  F + I AKRT RE++LL+HM HEN++ + D+  P      FNDVY+   LM  DL+ I++  Q L+++H Q+ +YQILRGLKYIHSA+++HRDLKPSNL +N +C+LKI DFGLAR T   D MT YV TRWYRAPE++LN   Y   +D+WSVGCI  EL+  + LFPG DH+ QL+L++ L+GTP +E   +  +E+A+ YI+ L   P+ +  + F   +PLA+DL+EKML  D  +RIT   ALAH Y    HD  DEP    P++  FE+  L  ++ K L Y E ++F P

+ ++ +   +Q  S +G GAYG VC+A    TG  VA+KK+  PF   + A RT RE+++LKH KHEN+I + ++  P  S E FN+VY++  LM  DL+ ++  Q L+DDH+Q+ IYQ LR +K +H +++IHRDLKPSNL +N +C+LK+ DFGLAR  D+              MT YVATRWYRAPE+ML    Y++ +D+WS GCI+AEL   R +FPG D+  QL LI  ++GTP ++  L+ I S  AR YI+SL   P      +F   NP  +DLL++MLV D  KRITA +AL H Y   YHDP+DEP  +P   SF   D     L   + K L ++E+ S

+ ++ +   +Q  S +G GAYG VC+A    TG  VA+KK+  PF   + A RT RE+++LKH KHEN+I + ++  P  S E FN+VY++  LM  DL+ ++  Q L+DDH+Q+ IYQ LR +K +H +++IHRDLKPSNL +N +C+LK+ DFGLAR  D+              MT  VATRWYRAPE+ML    Y++ +D+WS GCI+AEL   R +FPG D+  QL LI  ++GTP ++  L+ I S  AR YI+SL   P      +F   NP  +DLL++MLV D  KRITA +AL H Y   YHDP+DEP  +P   SF   D     L   + K L ++E+ S

+ ++ +   +Q  S +G GAYG VC+A    TG  VA+KK+  PF   + A RT RE+++LKH KHEN+I + ++  P  S E FN+VY++  LM  DL+ ++  Q L+DDH+Q+ IYQ LR +K +H +++IHRDLKPSNL +N +C+LK+ DFGLAR  D+              M  +VATRWYRAPE+ML    Y++ +D+WS GCI+AEL   R +FPG D+  QL LI  ++GTP ++  L+ I S  AR YI+SL   P      +F   NP  +DLL++MLV D  KRITA +AL H Y   YHDP+DEP  +P   SF   D     L   + K L ++E+ S

ChainA, Crystal Structure Of Fus3 With A Docking Motif From Ste7

Chain A, Crystal Structure Of Fus3 With A Docking Motif From Msg5

Chain A, Crystal Structure Of Fus3 With A Docking Motif From Far1

Chain A, Crystal Structure Of Fus3 In Complex With A Ste5 Peptide

Chain B, Crystal Structure Of Fus3 In Complex With A Ste5 Peptide

+ SG+YG+VCA  D++ G  VA+K++   F ++               KR  RE+RLL H  H N++GL D+F      EE   + +YLVT LM  DL  ++  Q++  +  H+Q+ +Y IL GL  +H A ++HRDL P N+ + ++ ++ I DF LAR    D   T YV  RWYRAPE+++ +  + + VD+WS GC+MAE+   + LF G+   +QL  I+ +VGTP  E +   SS SAR+Y++ SL+ +P   +  V   A+P+A+DL+ KML  +  +RI+  QAL H YF    DP             DE V D YD

ChainA, Map Kinase Lmampk10 From Leishmania Major In Complex With Sb203580

ChainA, Map Kinase Lmampk10 From Leishmania Major (1.95 Angs Resolution)

W++P+RY+    +G+G+YG VC A+D      VA+KK+ R F+ +I  KR  RE+ +L  + H++V+ +LD+  P + +E+F+++Y+V  +  +D   + +    LT+ H++ L+Y +L G+KY+HSA I+HRDLKP+N  VN+DC +K+ DFGLAR                           HT +   ++TG+V TRWYRAPE++L   +Y + +D+WS+GCI AELL                  G + FP       G D       + DQL +I  ++GTP  E ++ +  E A+ YI+   +    + A  F  ++  A+ LL++MLV + +KRIT  + LAH +F +

ChainA, Crystal Structure of the apo MapK from Toxoplasma Gondii, 25.m01780 or TGME49_007820

VP+ Y     +G G+YG V  A+D  T   VA+KK++R F+ +I  KR  RE+ +L  +K + +I L D+  P   L +F+++Y+V  +  +DL  + K    LT++H++ ++Y +L G  +IH + IIHRDLKP+N  +N+DC +K+ DFGLAR  + E                         +T +V TRWYRAPE++L   +Y +++DIWS GCI AELL          T R  LFPG+                  + DQL +I  ++GTP  + LK I+      YI+       +N    +   +   ++LLE ML  + +KRIT  QAL H Y 

ChainA, Crystal structure of Map Kinase from plasmodium berghei, PB000659.00.0

Chain B, Crystal structure of Map Kinase from plasmodium berghei, PB000659.00.0

F    ++ + +EVP +Y  L  +G GAYG  C+  D  TG +V++KK    F+ +   KR  RE+ +++   HEN++ ++++  P  R    F DVY+VT LM  D+N +++  Q L + H+Q+ +YQILRGLKY+HSA++ HRDLKP+NL  N  CELKI+DFGL+R  D    E+T YV TRWYR PE++L   +Y+  VDIWSVGCI AE+   + +FPG + +DQL++I + +G P A +++       R  ++ L ++P   +N   +  G   N   +D L KM  LD  KR TAA  LAH Y A  HD +DEP    P+  + ES  + + E +   + +++ + P

ChainA, Crystal Structure of MPK3 from Leishmania donovani, LdBPK_100540 in the presence of NVP-BBT594

EL   +  + +RY     +G+G+YG V  A DTK+ +R VA+K++++  F+ +I AKR  RE++LL H   +N+IGL ++ TP    E F+  Y+V  +M  DL  +++  Q+LT+ H+QF IYQ LR L  IHSA +IHRD+ P+N+ VN +C+LKI DFGLA+  +D+   MT YV  RWYRAPE+++    Y+  +D+W +GCI+ ELL  R LF G D ++QL  I+ ++GTP  E +  + S +A+ Y++  +  P+ ++   +  A+P A+DLL  MLV +  +RIT  QA+ H +  Q HD  D+ ++    +  E+    I + K   Y+E + F

ChainA, Crystal structure of MapK from Leishmania donovani, LDBPK_331470

Chain B, Crystal structure of MapK from Leishmania donovani, LDBPK_331470

+VP+ Y+    +G G+YG V  A+D      VA+KK++R F+ +I  KR  RE+ +L  +K + +I L D+  P   L +F+++Y+V  +  +DL  + K    LT+ HV+ ++Y +L G K+IH + IIHRDLKP+N  +N+DC +KI DFGLAR  +                             ++T +V TRWYRAPE++L   +Y  ++DIWS GCI AELL          T R  LFPG+       DH           DQL +I  ++GTP  E LK I+ +    YI+       ++ +  +   +   +DLLE ML  ++ KRIT  +AL+H Y       + E      + S E   L  D+W  L+

+N   +++  RY +L P+G G  G V +A D     RVA+KK  L+ P QS+ HA    RE+++++ + H+N++ + ++  P+ S        L E N VY+V   M  DL N+++   L ++H +  +YQ+LRGLKYIHSA+++HRDLKP+NL +N ED  LKI DFGLAR  D        ++  + T+WYR+P ++L+  +Y + +D+W+ GCI AE+LTG+TLF G   ++Q++LIL  +     E  +++ S     YI++    P      +  G +  AVD LE++L      R+TA +AL+H Y + Y  P DEP+

ChainA, Crystal Structure Of Human Mitogen Activated Protein Kinase 6 (mapk6)

Chain B, Crystal Structure Of Human Mitogen Activated Protein Kinase 6 (mapk6)

V  +Y+ +  +G GAYG V  + D +TG  VAVKK+   FQ+   A+RT+RE+ +L  +  HEN++ LL+V       +   DVYLV   M  DL+ +++   L   H Q+++YQ+++ +KY+HS  ++HRD+KPSN+ +N +C +K+ DFGL+R                     + DD+   +T YVATRWYRAPEI+L    Y + +D+WS+GCI+ E+L G+ +FPG+  ++QL+ I+ ++  P  E ++ I S  A+  I+SL +  ++           + N+ +  NP       A+DLL+K+L  + +KRI+A  AL H + + +H+P++EP  D     P + + +     ID++++L Y E+

ChainA, Crystal structure of MapK from Cryptosporidium Parvum, cgd2_1960

Chain B, Crystal structure of MapK from Cryptosporidium Parvum, cgd2_1960

E +Q +  +G G YG V  A +  TG  VA+KK+    ++        RE+ LLK + H N++ LLDV      +   N +YLV   +  DL   +    LT   +  +   ++Q+L+GL + HS  ++HRDLKP NL +N +  +K+ DFGLAR     +  Y   V T WYRAPEI+L   +Y+  VDIWS+GCI AE++T R LFPG   IDQL  I R +GTP   +   ++S    +Y  S  +  + +F+ V    +     LL +ML  D +KRI+A  ALAH +F

ChainA, Crystal Structure Of Phospho-Cdk2 In Complex With Cyclin B

E+YQ L  VG G YG V  A D++ G  VA+K++    +         RE+ LLK + H N++ L+DV    R L       LV   M  DL  ++   K  L D  ++  +YQ+LRG+ + H   I+HRDLKP NL +N D  LK+ DFGLAR     +  Y   V T WYRAP++++    Y+ +VDIWS+GCI AE++TG+ LFPG    DQL  I  ++GTP      ++  E      ++     K  ++++  G     +DLL  ML  D +KRI+A  A+ H YF

ChainA, Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with ADP bound.

ChainA, Cryptosporidium Parvum Cyclin-dependent Kinase Cgd5_2510 With Indirubin 3'-monoxime Bound

E +Q +  +G G YG V  A +  TG  VA+KK+    ++        RE+ LLK + H N++ LLDV      +   N +YLV   +  DL + +    LT   +  +   ++Q+L+GL + HS  ++HRDLKP NL +N +  +K+ DFGLAR     +  Y   V T WYRAPEI+L   +Y+  VDIWS+GCI AE++T R LFPG   IDQL  I R +GTP   +   ++S    +Y  S  +  + +F+ V    +     LL +ML  D +KRI+A  ALAH +F     P

ChainA, Thr 160 Phosphorylated Cdk2 H84s, Q85m, K89d - Human Cyclin A3 Complex With Atp

Chain C, Thr 160 Phosphorylated Cdk2 H84s, Q85m, K89d - Human Cyclin A3 Complex With Atp

ChainA, Thr 160 Phosphorylated Cdk2 H84s, Q85m, K89d - Human Cyclin A3 Complex With The Inhibitor Nu6102

Chain C, Thr 160 Phosphorylated Cdk2 H84s, Q85m, K89d - Human Cyclin A3 Complex With The Inhibitor Nu6102

Chain A, Thr 160 Phosphorylated Cdk2 H84s, Q85m, K89d - Human Cyclin A3 Complex With The Inhibitor Ro3306

Chain C, Thr 160 Phosphorylated Cdk2 H84s, Q85m, K89d - Human Cyclin A3 Complex With The Inhibitor Ro3306

E +Q +  +G G YG V  A +  TG  VA+KK+    ++        RE+ LLK + H N++ LLDV      +   N +YLV   +  DL   +    LT   +  +   ++Q+L+GL + HS  ++HRDLKP NL +N +  +K+ DFGLAR     +  Y   V T WYRAPEI+L   +Y+  VDIWS+GCI AE++T R LFPG   IDQL  I R +GTP   +   ++S    +Y  S  +  + +F+ V    +     LL +ML  D +KRI+A  ALAH +F     P

ChainA, Thr 160 Phosphorylated Cdk2 H84s, Q85m, Q131e - Human Cyclin A3 Complex With Atp

Chain C, Thr 160 Phosphorylated Cdk2 H84s, Q85m, Q131e - Human Cyclin A3 Complex With Atp

ChainA, Thr 160 Phosphorylated Cdk2 H84s, Q85m, Q131e - Human Cyclin A3 Complex With The Inhibitor Ro3306

Chain C, Thr 160 Phosphorylated Cdk2 H84s, Q85m, Q131e - Human Cyclin A3 Complex With The Inhibitor Ro3306

ChainA, Thr 160 Phosphorylated Cdk2 K89d, Q131e - Human Cyclin A3 Complex With The Inhibitor Ro3306

Chain C, Thr 160 Phosphorylated Cdk2 K89d, Q131e - Human Cyclin A3 Complex With The Inhibitor Ro3306

ChainA, Thr 160 Phosphorylated Cdk2-Human Cyclin A3 Complex With The Inhibitor Indirubin-5-Sulphonate Bound

Chain C, Thr 160 Phosphorylated Cdk2-Human Cyclin A3 Complex With The Inhibitor Indirubin-5-Sulphonate Bound

Chain A, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A

Chain C, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A

Chain C, Structure Of Phopsho-cdk2-cyclin A In Complex With An Atp-competitive Inhibitor

Chain A, Thr 160 Phosphorylated Cdk2 Wt - Human Cyclin A3 Complex With The Inhibitor Nu6102

Chain C, Thr 160 Phosphorylated Cdk2 Wt - Human Cyclin A3 Complex With The Inhibitor Nu6102

ChainA, Thr 160 Phosphorylated Cdk2 Wt - Human Cyclin A3 Complex With The Inhibitor Ro3306

Chain C, Thr 160 Phosphorylated Cdk2 Wt - Human Cyclin A3 Complex With The Inhibitor Ro3306

ChainA, Structure-based Design Of C8-substituted O6- Cyclohexylmethoxyguanine Cdk1 And 2 Inhibitors.

Chain C, Structure-based Design Of C8-substituted O6- Cyclohexylmethoxyguanine Cdk1 And 2 Inhibitors.

Chain A, Structure-based Design Of C8-substituted O6- Cyclohexylmethoxyguanine Cdk1 And 2 Inhibitors.

ChainA, Crystal Structure Of Human Cyclin-dependent Kinase 2 Complexed With A Nucleoside Inhibitor

ChainA, Imidazopyridines: A Potent And Selective Class Of Cyclin-dependent Kinase Inhibitors Identified Through Structure-based Hybridisation

ChainA, Thr 160 Phosphorylated Cdk2 Q131e - Human Cyclin A3 Complex With The Inhibitor Ro3306

Chain C, Thr 160 Phosphorylated Cdk2 Q131e - Human Cyclin A3 Complex With The Inhibitor Ro3306

ChainA, Thr 160 Phosphorylated Cdk2 Q131e - Human Cyclin A3 Complex With Atp

Chain C, Thr 160 Phosphorylated Cdk2 Q131e - Human Cyclin A3 Complex With Atp

ChainA, Structure of pCDK2/CyclinA bound to ADP and 2 Magnesium ions

Chain C, Structure of pCDK2/CyclinA bound to ADP and 2 Magnesium ions

ChainA, Structure Of Human Thr160-phospho Cdk2/cyclin A Complexed With A 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine Inhibitor

Chain C, Structure Of Human Thr160-phospho Cdk2/cyclin A Complexed With A 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine Inhibitor

Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With A 6-Cyclohexylmethyloxy-2-Anilino-Purine Inhibitor

Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With A 6-Cyclohexylmethyloxy-2-Anilino-Purine Inhibitor

Chain A, Structure-based Design Of C8-substituted O6-cyclohexylmethoxyguanine Cdk1 And 2 Inhibitors.

Chain C, Structure-based Design Of C8-substituted O6-cyclohexylmethoxyguanine Cdk1 And 2 Inhibitors.

ChainA, Structure Of Cdk2 In Complex With Cyclin A And A 2-amino-4- Heteroaryl-pyrimidine Inhibitor

Chain C, Structure Of Cdk2 In Complex With Cyclin A And A 2-amino-4- Heteroaryl-pyrimidine Inhibitor

Chain A, Structure Of Cdk2 In Complex With Cyclin A And A 2-amino-4- Heteroaryl-pyrimidine Inhibitor

ChainA, Thr 160 Phosphorylated Cdk2 Wt - Human Cyclin A3 Complex With Atp

Chain C, Thr 160 Phosphorylated Cdk2 Wt - Human Cyclin A3 Complex With Atp

Chain A, Structure Of Cdk2-Cyclin A Complexed With 8-Anilino-1- Methyl-4,5-Dihydro-1h-Pyrazolo[4,3-H] Quinazoline-3- Carboxylic Acid

Chain C, Structure Of Cdk2-Cyclin A Complexed With 8-Anilino-1- Methyl-4,5-Dihydro-1h-Pyrazolo[4,3-H] Quinazoline-3- Carboxylic Acid

Chain A, Optimisation Of 6,6-Dimethyl Pyrrolo 3,4-C Pyrazoles: Identification Of Pha-793887, A Potent Cdk Inhibitor Suitable For Intravenous Dosing

Chain C, Optimisation Of 6,6-Dimethyl Pyrrolo 3,4-C Pyrazoles: Identification Of Pha-793887, A Potent Cdk Inhibitor Suitable For Intravenous Dosing

Chain A, Structure Of Cdk2-Cyclin A With A Pyrazolo(4,3-H) Quinazoline-3-Carboxamide Inhibitor

Chain C, Structure Of Cdk2-Cyclin A With A Pyrazolo(4,3-H) Quinazoline-3-Carboxamide Inhibitor

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Purvalanol B

Chain A, Crystal Structure Of The Human Cdk2 Kinase Complex With Cell Cycle-Regulatory Protein Ckshs1

Chain A, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE

Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline

Chain A, Crystal Structure Of Murine Gamma Herpesvirus Cyclin Complexed To Human Cyclin Dependent Kinase 2

Chain C, Crystal Structure Of Murine Gamma Herpesvirus Cyclin Complexed To Human Cyclin Dependent Kinase 2

Chain A, The Structure Of Cyclin-dependent Kinase 2 (cdk2) In Complex With An Oxindole Inhibitor

Chain A, The Structure Of Cdk2/cyclin A In Complex With An Oxindole Inhibitor

Chain C, The Structure Of Cdk2/cyclin A In Complex With An Oxindole Inhibitor

Chain A, The structure of cyclin-dependent kinase 2 (CDK2) in complex with 4-[(6-amino-4-pyrimidinyl)amino]benzenesulfonamide

Chain A, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717

Chain P, Crystal Structure Of Human Cdk2 (Unphosphorylated) In Complex With Pkf049-365

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Cdk4 Inhibitor

Chain A, CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide

Chain A, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE

Chain A, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE

Chain A, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE

Chain A, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE

Chain A, Human Cyclin Dependent Protein Kinase 2 In Complex With The Inhibitor 2-Amino-6-[(R)-Pyrrolidino-5'-Yl]methoxypurine

Chain A, Human Cyclin Dependent Protein Kinase 2 In Complex With The Inhibitor 2-Amino-6-[cyclohex-3-Enyl]methoxypurine

Chain A, The Structure Of Cyclin Dependent Kinase 2 (Ckd2) With A Trisubstituted Naphthostyril Inhibitor

Chain A, Cyclin A Binding Groove Inhibitor H-arg-arg-leu-ile-phe-nh2

Chain C, Cyclin A Binding Groove Inhibitor H-arg-arg-leu-ile-phe-nh2

Chain A, Cyclin A Binding Groove Inhibitor Ac-arg-arg-leu-asn-(m-cl-phe)-nh2

Chain C, Cyclin A Binding Groove Inhibitor Ac-arg-arg-leu-asn-(m-cl-phe)-nh2

Chain A, Cyclin A Binding Groove Inhibitor H-cit-cit-leu-ile-(p-f-phe)-nh2

Chain C, Cyclin A Binding Groove Inhibitor H-cit-cit-leu-ile-(p-f-phe)-nh2

Chain A, Cyclin A Binding Groove Inhibitor H-arg-arg-leu-asn-(p-f-phe)-nh2

Chain C, Cyclin A Binding Groove Inhibitor H-arg-arg-leu-asn-(p-f-phe)-nh2

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2- Ylamine

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor N-[4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-yl]- N'-hydroxyiminoformamide

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- (4-trifluoromethyl-phenyl)-amine

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2- Ylamino]-Phenol

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)- Pyrimidin-2-Ylamino]-Phenol

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2- Yl]-(3-Nitro-Phenyl)-Amine

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor N-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]- N',N'-Dimethyl-Benzene-1,4-Diamine

Chain A, Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly

Chain C, Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly

Chain C, Crystal Structure Of Human Cdk2 In Complex With The Inhibitor Olomoucine.

Chain A, screening for fragment binding by X-ray crystallography

Chain A, Crystal Structure Of Human Cdk2 Complexed With A Pyrazolo[1, 5-A]pyrimidine Inhibitor

Chain A, Human Cyclin Dependent Protein Kinase 2 In Complex With The Inhibitor 5-Bromo-Indirubine

Chain A, Human Cyclin Dependent Protein Kinase 2 In Complex With The Inhibitor 4-Hydroxypiperindinesulfonyl-Indirubine

Chain A, Human Cyclin Dependent Kinase 2 (Cdk2) Complexed With Dph- 042562

Chain A, Human Cyclin Dependent Kinase 2 (Cdk2) Complexed With Din- 234325

Chain A, Human Cyclin Dependent Kinase 2 (Ckd2)complexed With Din- 232305

Chain A, Human Cyclin Dependent Kinase 2 (Cdk2) Complexed With Indenopyraxole Din-101312

Chain A, Crystal Structure Of The Human Cdk2 Complexed With The Triazolopyrimidine Inhibitor

Chain A, Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor

Chain A, Crystal Structure Of Cdk2 With An Aminoimidazo Pyridine Inhibitor

Chain X, Human Cdk2 In Complex With Olomoucine Ii, A Novel 2,6,9- Trisubstituted Purine Cyclin-Dependent Kinase Inhibitor

Chain A, Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design

Chain C, Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design

Chain A, Human Cyclin-dependent Kinase 2 In Complex With Roscovitine

Chain A, Cyclin Dependent Kinase 2 (Cdk2) With Diaminopyrimidine Inhibitor

Chain A, Cdk2CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR

Chain C, Cdk2CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR

Chain A, 4-Arylazo-3,5-Diamino-1h-Pyrazole Cdk Inhibitors: Sar Study, Crystal Structure In Complex With Cdk2, Selectivity, And Cellular Effects

Chain A, Replace: A Strategy For Iterative Design Of Cyclin Binding Groove Inhibitors

Chain C, Replace: A Strategy For Iterative Design Of Cyclin Binding Groove Inhibitors

Chain A, Crystal Structure Of Human Cdk2 Complexed With A Thiazolidinone Inhibitor

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Staurosporine

Chain A, Crystal Structure Of Cdk2 In Complex With Macrocyclic Aminopyrimidine

Chain A, Identification Of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- Pyrazole-3-carboxamide (at7519), A Novel Cyclin Dependent Kinase Inhibitor Using Fragment-based X-ray Crystallography And Structure Based Drug Design.

Chain A, Identification Of N-(4-Piperidinyl)-4-(2,6- Dichlorobenzoylamino)-1h-Pyrazole-3-Carboxamide (At7519), A Novel Cyclin Dependent Kinase Inhibitor Using Fragment- Based X-Ray Crystallography And Structure Based Drug Design

Chain A, Identification Of N-(4-Piperidinyl)-4-(2,6- Dichlorobenzoylamino)-1h-Pyrazole-3-Carboxamide (At7519), A Novel Cyclin Dependent Kinase Inhibitor Using Fragment- Based X-Ray Crystallography And Structure Based Drug Design.

Chain A, Crystal Structure Of A 3-Aminoindazole Compound With Cdk2

Chain A, Structure Of Cdk2 In Complex With An Imidazolyl Pyrimidine, Compound 5b

Chain A, Cdk2CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR

Chain C, Cdk2CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR

Chain A, Fragment-Based Discovery Of The Pyrazol-4-Yl Urea (At9283), A Multi-Targeted Kinase Inhibitor With Potent Aurora Kinase Activity

Chain A, Cdk-2-Cyclin Complex With Indazole Inhibitor 9 Bound At Its Active Site

Chain C, Cdk-2-Cyclin Complex With Indazole Inhibitor 9 Bound At Its Active Site

Chain A, Crystal structure of a benzthiophene inhibitor bound to human Cyclin-dependent Kinase-2 (CDK-2)

Chain A, Truncation And Optimisation Of Peptide Inhibitors Of Cdk2, Cyclin A Through Structure Guided Design

Chain C, Truncation And Optimisation Of Peptide Inhibitors Of Cdk2, Cyclin A Through Structure Guided Design

Chain A, Crystal Structure Of Cdk2 With Sar57, An Aminoindazole Type Inhibitor

Chain A, Crystal Structure Of Cdk2 With Sar60, An Aminoindazole Type Inhibitor

Chain A, Crystal Structure Of Cdk2 With Sar37, An Aminoindazole Type Inhibitor

Chain A, Discovery And Characterisation Of 2-Anilino-4-(Thiazol-5-Yl) Pyrimidine Transcriptional Cdk Inhibitors As Anticancer Agents

Chain A, The Structure Of Cyclin Dependent Kinase 2 (Ckd2) With A Pyrazolobenzodiazepine Inhibitor

Chain A, Crystal Structure Of Cdk2 In Complex With Inhibitor Bs-194

Chain A, Crystal Structure Of Cdk2 With A 2-Aminopyrimidine Compound

Chain A, Crystal Structure of the CDK2/Cyclin A complex with oxindole inhibitor

Chain C, Crystal Structure of the CDK2/Cyclin A complex with oxindole inhibitor

Chain A, Human Cyclin Dependent Kinase 2 (cdk2) Bound To Azabenzimidazole Derivative

Chain A, Crystal Structure Of Cdk2 In Complex With Pan-cdk Inhibitor

Chain A, Crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with (2s)-n-(5-(((5-tert-butyl-1,3-oxazol-2-yl)methyl)sulfanyl)-1,3-thiazol-2-yl)-2-phenylpropanamide

Chain A, Crystal Structure Of Cdk2 In Complex With Pyrazolopyrimidine Inhibitor

Chain A, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]-4-PIPERIDINECARBOXAMIDE (BMS-387032)

Chain A, Structure Of Cyclin-dependent Kinase 2 With Small-molecule Ligand 4-fluorobenzoic Acid (at222) In An Alternate Binding Site.

Chain A, Structure Of Cyclin-dependent Kinase 2 With Small-molecule Ligand 3-(4,7-dichloro-1h-indol-3-yl)prop-2-yn-1-ol (at17833) In An Alternate Binding Site.

Chain A, Crystal Structure Of Cdk2 In Complex With 2-imidazol-1-yl-1h- Benzimidazole Processed With The Crystaldirect Automated Mounting And Cryo-cooling Technology

Chain A, Crystal Structure Of Cdk2 In Complex With 6-methoxy-7h- Purine Processed With The Crystaldirect Automated Mounting And Cryo-cooling Technology

Chain A, Crystal Structure Of Cdk2 In Complex With 7-hydroxy-4-(Morpholinomethyl)chromen-2-one Processed With The Crystaldirect Automated Mounting And Cryo-cooling Technology

Chain A, Crystal Structure Of Cdk2 In Complex With 6-chloro-7h- Purine Processed With The Crystaldirect Automated Mounting And Cryo-cooling Technology

Chain A, Crystal Structure Of Cdk2 In Complex With N-(9h-purin-6-yl) Thiophene-2-carboxamide Processed With The Crystaldirect Automated Mounting And Cryo-cooling Technology

Chain A, Crystal Structure Of Cdk2 In Complex With 2,4,6-trioxo-1- Phenyl-hexahydropyrimidine-5-carboxamide Processed With The Crystaldirect Automated Mounting And Cryo-cooling Technology

Chain A, Crystal Structure Of Cdk2 Processed With The Crystaldirect Automated Mounting And Cryo-cooling Technology

Chain A, Crystal Structure Of Bay 1000394 (roniciclib) Bound To Cdk2

Chain A, Crystal Structure Of (r,s)-s-{4-[(5-bromo-4-{[(2r,3r)-2-hydroxy-1- Methylpropyl]oxy}- Pyrimidin-2-yl)amino]phenyl}-s- Cyclopropylsulfoximide Bound To Cdk2

Chain A, Crystal Structure Of Cdk2 In Complex With Inhibitor Icec0942

Chain A, Crystal Structure Of Cdk2 In Complex With Inhibitor Icec0943

ChainA, Phosphorylated Cyclin-Dependent Kinase-2 Bound To Cyclin A

Chain C, Phosphorylated Cyclin-Dependent Kinase-2 Bound To Cyclin A

Chain B, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2

Chain C, Crystal Structure Of The Human Cdk2 Complexed With The Triazolopyrimidine Inhibitor

Chain C, Crystal Structure Of Human Cdk2 Complexed With A Thiazolidinone Inhibitor

Chain A, Structure Of Pcdk2/cyclina Bound To Adp And 1 Magnesium Ion

Chain C, Structure Of Pcdk2/cyclina Bound To Adp And 1 Magnesium Ion

ChainA, Structure Of Human Thr160-Phospho Cdk2-Cyclin A Complexed With A Bisanilinopyrimidine Inhibitor

Chain C, Structure Of Human Thr160-Phospho Cdk2-Cyclin A Complexed With A Bisanilinopyrimidine Inhibitor

Chain A, Structure Of Human Thr160-Phospho Cdk2-Cyclin A Complexed With A Bisanilinopyrimidine Inhibitor

ChainA, Cdk2 In Complex With The Imidazole Pyrimidine Amide, Compound (S)-8b

Chain A, Novel Cdk-5 Inhibitors - Crystal Structure Of Inhibitor Efp With Cdk-2

Chain A, Novel Cdk-5 Inhibitors - Crystal Structure Of Inhibitor Efq With Cdk-2

Chain A, Human Cyclin-Dependent Kinase 2 Phosphorylated On Thr 160

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Nu2058

Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Nu6027

Chain A, Cdk2 In Complex With A Disubstituted 4, 6-Bis Anilino Pyrimidine Cdk4 Inhibitor

Chain A, Cdk2 In Complex With A Disubstituted 2, 4-Bis Anilino Pyrimidine Cdk4 Inhibitor

Chain A, Crystal Structure Of Cyclin-Dependent Kinase 2 With Inhibitor

Chain A, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE

Chain A, Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor

Chain A, Imidazopyridines: A Potent And Selective Class Of Cyclin-Dependent Kinase Inhibitors Identified Through Structure-Based Hybridisation

Chain A, Structure Of Cdk2 In Complex With An Imidazolyl Pyrimidine, Compound 5c

Chain A, Crystal Structure Of Cyclin-dependent Kinase 2 With Inhibitor

Chain A, Crystal Structure Of The Cdk2 In Complex With Aminopyrazole Inhibitor

Chain A, Crystal structure of the cdk2 in complex with aminopyrazole inhibitor

Chain A, Crystal Structure Of The Cdk2 In Complex With Thiazolylpyrimidine Inhibitor

Chain A, Crystal Structure Of The Cdk2 In Complex With Oxindole Inhibitor

Chain A, Structure of CDK2 in complex with a benzimidazopyrimidine

ChainA, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu2058

Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu2058

Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6094

Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6094

Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6086

Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6086

Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6102

Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6102

Chain A, Cdk2CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT Peptide From E2f

Chain C, Cdk2CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT Peptide From E2f

Chain A, Cdk2CYCLIN A IN COMPLEX WITH AN 11-Residue Recruitment Peptide From Retinoblastoma-Associated Protein

Chain C, Cdk2CYCLIN A IN COMPLEX WITH AN 11-Residue Recruitment Peptide From Retinoblastoma-Associated Protein

Chain A, Cdk2CYCLIN A IN COMPLEX WITH AN 11-Residue Recruitment Peptide From P53

Chain C, Cdk2CYCLIN A IN COMPLEX WITH AN 11-Residue Recruitment Peptide From P53

Chain A, Cdk2CYCLIN A IN COMPLEX WITH AN 11-Residue Recruitment Peptide From P27

Chain C, Cdk2CYCLIN A IN COMPLEX WITH AN 11-Residue Recruitment Peptide From P27

Chain A, Cdk2/cyclin A In Complex With An 11-residue Recruitment Peptide From P107

Chain C, Cdk2/cyclin A In Complex With An 11-residue Recruitment Peptide From P107

Chain A, Structural And Thermodynamic Consequences Of Cyclization Of Peptide Ligands For The Recruitment Site Of Cyclin A

Chain C, Structural And Thermodynamic Consequences Of Cyclization Of Peptide Ligands For The Recruitment Site Of Cyclin A

Chain A, Cdk2/cyclin A Covalent Complex With 6-(cyclohexylmethoxy)-n-(4- (vinylsulfonyl)phenyl)-9h-purin-2-amine (nu6300)

Chain C, Cdk2/cyclin A Covalent Complex With 6-(cyclohexylmethoxy)-n-(4- (vinylsulfonyl)phenyl)-9h-purin-2-amine (nu6300)

ChainA, CDK-2 with indazole inhibitor 17 bound at its active site

Chain A, Cdk-2 With Indazole Inhibitor 9 Bound At Its Active Site

ChainA, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor 2-amino-6-(3'-methyl-2'-oxo)butoxypurine

Chain A, Co-crystal Structure Of 6-cyclohexylmethoxy-8-isopropyl-9h-purin-2- Ylamine And Monomeric Cdk2

Chain A, Modulating The Interaction Between Cdk2 And Cyclin A With A Quinoline- Based Inhibitor

ChainA, Structure Of Phosphorylated Thr160 Cdk2CYCLIN A IN COMPLEX WITH THE Inhibitor Meriolin 3

Chain C, Structure Of Phosphorylated Thr160 Cdk2CYCLIN A IN COMPLEX WITH THE Inhibitor Meriolin 3

Chain A, Structure Of Phosphorylated Thr160 Cdk2/cyclin A In Complex With The Inhibitor Meriolin 5

Chain C, Structure Of Phosphorylated Thr160 Cdk2/cyclin A In Complex With The Inhibitor Meriolin 5

Chain A, Structure Of Phosphorylated Thr160 Cdk2CYCLIN A IN COMPLEX With The Inhibitor Variolin B

Chain C, Structure Of Phosphorylated Thr160 Cdk2CYCLIN A IN COMPLEX With The Inhibitor Variolin B

Chain C, Phosphorylated Cdk2-Cyclyin A-Substrate Peptide Complex

Chain A, Pcdk2CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE

Chain C, Pcdk2CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE

Chain A, The Structure Of Phospho-cdk2/cyclin A In Complex With The Inhibitor 4,5,6,7-tetrabromobenzotriazole (tbs)

Chain C, The Structure Of Phospho-cdk2/cyclin A In Complex With The Inhibitor 4,5,6,7-tetrabromobenzotriazole (tbs)

Chain A, The Crystal Structure Of Cdk2 Cyclin A In Complex With A Substrate Peptide Derived From Cdc Modified With A Gamma- Linked Atp Analogue

Chain C, The Crystal Structure Of Cdk2 Cyclin A In Complex With A Substrate Peptide Derived From Cdc Modified With A Gamma- Linked Atp Analogue

Chain A, Crystal Structure Of Phospho-Cdk2 Cyclin A In Complex With A Peptide Containing Both The Substrate And Recruitment Sites Of Cdc6

Chain C, Crystal Structure Of Phospho-Cdk2 Cyclin A In Complex With A Peptide Containing Both The Substrate And Recruitment Sites Of Cdc6

Chain A, Structure Of Thr 160 Phosphorylated Cdk2CYCLIN A IN COMPLEX WITH THE Inhibitor Nu6271

Chain C, Structure Of Thr 160 Phosphorylated Cdk2CYCLIN A IN COMPLEX WITH THE Inhibitor Nu6271

Chain A, Structure Of Phosphorylated Thr160 Cdk2CYCLIN A IN COMPLEX With The Inhibitor Cr8

Chain C, Structure Of Phosphorylated Thr160 Cdk2CYCLIN A IN COMPLEX With The Inhibitor Cr8

Chain A, Structure Of Phosphorylated Thr160 Cdk2CYCLIN A IN COMPLEX With The Inhibitor Roscovitine

Chain C, Structure Of Phosphorylated Thr160 Cdk2CYCLIN A IN COMPLEX With The Inhibitor Roscovitine

Chain A, Structure Of Thr 160 Phosphorylated Cdk2CYCLIN A IN Complex With The Inhibitor N-&-N1

Chain C, Structure Of Thr 160 Phosphorylated Cdk2CYCLIN A IN Complex With The Inhibitor N-&-N1

Chain A, The X-ray Co-crystal Structure Of Human Cdk2/cycline And Dinaciclib.

Chain A, Structure Of Phopsho-cdk2-cyclin A In Complex With An Atp-competitive Inhibitor

ChainA, Structure Of Cdk2 In Complex With A Pyrazolo[4,3-D]pyrimidine Bioisostere Of Roscovitine.

ChainA, Structure Of Human Thr160-Phospho Cdk2-Cyclin A F82h-L83v- H84d Mutant With An O6-Cyclohexylmethylguanine Inhibitor

Chain C, Structure Of Human Thr160-Phospho Cdk2-Cyclin A F82h-L83v- H84d Mutant With An O6-Cyclohexylmethylguanine Inhibitor

ChainA, Human Cyclin Dependent Kinase 2 Complexed With The Cdk4 Inhibitor

E  E +Q +  +G G YG V  A +  TG  VA+KK+    ++        RE+ LLK + H N++ LLDV      +   N +YLV   +  DL   +    LT   +  +   ++Q+L+GL + HS  ++HRDLKP NL +N +  +K+ DFGLAR     +  Y   V T WYRAPEI+L   +Y+  VDIWS+GCI AE++T R LFPG   IDQL  I R +GTP   +   ++S    +Y  S  +  + +F+ V    +     LL +ML  D +KRI+A  ALAH +F     P

ChainA, Cdk2 In Complex With Two Molecules Of 8-Anilino-1-Naphthalene Sulfonate

Chain A, Cdk2 In Complex With 3 Molecules Of 8-Anilino-1-Naphthalene Sulfonate

Chain A, Cdk2 In Complex With Staurosporine And 2 Molecules Of 8-Anilino-1- Naphthalene Sulfonic Acid

Chain A, Crystal Structure Of Human Cdk2-spy1-p27 Ternary Complex

++Y+ ++ +G GAYG V  A D K G R VA+K++            T RE+ +L+H++   H NV+ L DV T +R+  E   + LV   +  DL      V    +  + ++ +++Q+LRGL ++HS  ++HRDLKP N+ V    ++K+ DFGLAR    +M  T  V T WYRAPE++L    Y   VD+WSVGCI AE+   + LF G+  +DQL  IL ++G PG E   +      R    S +  P   F       + L  DLL K L  +  KRI+A  AL+H YF

Chain A, Liganded X-ray crystal structure of cyclin dependent kinase 6 (CDK6)

Chain A, The X-ray Co-crystal Structure Of Human Cdk6 And Palbociclib.

Chain A, The X-ray Co-crystal Structure Of Human Cdk6 And Abemaciclib.

Chain A, The X-ray Co-crystal Structure Of Human Cdk6 And Ribociclib.

++Y+ ++ +G GAYG V  A D K G R VA+K++            T RE+ +L+H++   H NV+ L DV T +R+  E   + LV   +  DL    + V    +  + ++ +++Q+LRGL ++HS  ++HRDLKP N+ V    ++K+ DFGLAR    +M  T  V T WYRAPE++L    Y   VD+WSVGCI AE+   + LF G+  +DQL  IL ++G PG E   +      R    S +  P   F       + L  DLL K L  +  KRI+A  AL+H YF

ChainB, Crystal Structure Of A Complex Of Human Cdk6 And A Viral Cyclin

Chain B, Crystal Structure Of A Human Cyclin-Dependent Kinase 6 Complex With A Flavonol Inhibitor, Fisetin

Chain B, X-Ray Structure Of Human Cdk6-Vcyclin In Complex With The Inhibitor Pd0332991

Chain B, X-ray structure of human CDK6-Vcyclinwith the inhibitor aminopurvalanol

ChainA, Mechanism Of G1 Cyclin Dependent Kinase Inhibition From The Structures Cdk6-P19ink4d Inhibitor Complex

Chain C, Mechanism Of G1 Cyclin Dependent Kinase Inhibition From The Structures Cdk6-P19ink4d Inhibitor Complex

Chain A, Mechanism Of G1 Cyclin Dependent Kinase Inhibition From The Structure Of The Cdk6-P16ink4a Tumor Suppressor Complex

Chain A, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX

Chain E, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX

Chain B, Crystal structure of a CDK6/Vcyclin complex with inhibitor bound

E +Q +  +G G YG V  A +  TG  VA+ K+    ++        RE+ LLK + H N++ LLDV      +   N +YLV   +  DL   +    LT   +  +   ++Q+L+GL + HS  ++HRDLKP NL +N +  +K+ DFGLAR     +  Y   V T WYRAPEI+L   +Y+  VDIWS+GCI AE++T R LFPG   IDQL  I R +GTP   +   ++S    +Y  S  +  + +F+ V    +     LL +ML  D +KRI+A  ALAH +F     P

ChainA, Cdk2 In Complex With A Disubstituted 2, 4-Bis Anilino Pyrimidine Cdk4 Inhibitor

ChainA, Imidazopyridines: A Potent And Selective Class Of Cyclin-Dependent Kinase Inhibitors Identified Through Structure-Based Hybridisation

E +Q +  +G G  G V  A +  TG  VA+KK+    ++        RE+ LLK + H N++ LLDV      +   N +YLV   +  DL   +    LT   +  +   ++Q+L+GL + HS  ++HRDLKP NL +N +  +K+ DFGLAR     +  Y   V T WYRAPEI+L   +Y+  VDIWS+GCI AE++T R LFPG   IDQL  I R +GTP   +   ++S    +Y  S  +  + +F+ V    +     LL +ML  D +KRI+A  ALAH +F     P

ChainA, Mechanism Of Cdk Inhibition By Active Site Phosphorylation: Cdk2 Y15p T160p In Complex With Cyclin A Structure

Chain C, Mechanism Of Cdk Inhibition By Active Site Phosphorylation: Cdk2 Y15p T160p In Complex With Cyclin A Structure

E  E +Q +  +G G YG V  A +  TG  VA+ K+    ++        RE+ LLK + H N++ LLDV      +   N +YLV   +  DL   +    LT   +  +   ++Q+L+GL + HS  ++HRDLKP NL +N +  +K+ DFGLAR     +  Y   V T WYRAPEI+L   +Y+  VDIWS+GCI AE++T R LFPG   IDQL  I R +GTP   +   ++S    +Y  S  +  + +F+ V    +     LL +ML  D +KRI+A  ALAH +F     P

E+Y  L  +G G YG V  A     G   A+KK+    +       T RE+ +LK +KH N++ L DV    + L       LV   +  DL  ++  C+  L     +  + Q+L G+ Y H   ++HRDLKP NL +N + ELKI DFGLAR     +  Y   V T WYRAP++++    Y+ T+DIWSVGCI AE++ G  LFPG    DQL  I R++GTP ++    ++      Y  +      + + +   G +   +DLL KML LD ++RITA QAL HAYF +

ChainA, Structure Of P. Falciparum Pfpk5-Indirubin-5-Sulphonate Ligand Complex

Chain B, Structure Of P. Falciparum Pfpk5-Indirubin-5-Sulphonate Ligand Complex

E+Y  L  +G G YG V  A     G   A+KK+    +       T RE+ +LK +KH N++ L DV    + L       LV   +  DL  ++  C+  L     +  + Q+L G+ Y H   ++HRDLKP NL +N + ELKI DFGLAR     +  Y   + T WYRAP++++    Y+ T+DIWSVGCI AE++ G  LFPG    DQL  I R++GTP ++    ++      Y  +      + + +   G +   +DLL KML LD ++RITA QAL HAYF +

Chain A, Structure Of P. Falciparum Pfpk5-Purvalanol B Ligand Complex

Chain B, Structure Of P. Falciparum Pfpk5-Purvalanol B Ligand Complex

E Y  L  +G G Y +V       T + VA+K++    +         RE+ LLK +KH N++ L D+    +SL       LV   +  DL   +  C  + + H V+  ++Q+LRGL Y H   ++HRDLKP NL +NE  ELK+ DFGLAR        Y   V T WYR P+I+L    Y+  +D+W VGCI  E+ TGR LFPG+   +QL  I R++GTP  E    I S+E  + Y       PK     +   A  L     DLL K+L  +   RI+A  A+ H +F

ChainA, Crystal Structure Of The Pctaire1 Kinase In Complex With Ind E804

Chain A, Crystal Structure Of The Pctaire1 Kinase In Complex With Inhibitor

Chain B, Crystal Structure Of The Pctaire1 Kinase In Complex With Inhibitor

E Y  +  +G G YG V       TG  VA+KK+    +         RE+ LLK ++H N++ L DV      L + + +YL+   +  DL    ++I   Q +    V+  +YQIL+G+ + HS  ++HRDLKP NL +++   +K+ DFGLAR     +  Y   V T WYR+PE++L    Y+  VDIWS+G I AEL T + LF G   IDQL  I R +GTP  E+  ++  ES ++Y  +  +    + A+     +   +DLL KML+ D  KRI+   AL H YF

Chain A, Ternary Complex Of Human Proteins Cdk1, Cyclin B And Cks2, Bound To An Inhibitor

+RY+ L  +G G + +V  A D  T   VA+KK+    +S       +   RE++LL+ + H N+IGLLD F         +++ LV   M  DL  I+K   L  T  H++  +   L+GL+Y+H   I+HRDLKP+NL ++E+  LK+ DFGLA+        Y   V TRWYRAPE++     Y   VD+W+VGCI+AELL      PG   +DQL  I   +GTP  E    + S    +Y+ +    P +   ++F  A    +DL++ + + +   RITA QAL   YF+    P

++Y+ L  +G G YG+V  A + +T   VA+K++              RE+ LLK +KH+N++ L DV    + L       LV      DL      C   L  + V+  ++Q+L+GL + HS +++HRDLKP NL +N + ELK+ DFGLAR     +  Y   V T WYR P+++     Y+ ++D+WS GCI AEL   GR LFPG D  DQLK I RL+GTP  E    ++     +Y          +  NV    N    DLL+ +L  +  +RI+A +AL H YF+ +  P

ChainA, Crystal Structure Of Compound 4a In Complex With Cdk5, Showing An Unusual Binding Mode To The Hinge Region Via A Water Molecule

Chain B, Crystal Structure Of Compound 4a In Complex With Cdk5, Showing An Unusual Binding Mode To The Hinge Region Via A Water Molecule

+++ L  +G+G Y +V    +  TG  VA+K++    +    +    RE+ L+K +KHEN++ L DV      L    EF D  L  ++    + N  +  +L  + V++  +Q+L+GL + H   I+HRDLKP NL +N+  +LK+ DFGLAR      +  +  V T WYRAP++++    Y+ ++DIWS GCI+AE++TG+ LFPGT+  +QLKLI  ++GTP   L   ++      Y  ++ Q P  +   V       PL    +D L  +L L+ D R++A QAL H +FA+Y+

ChainA, Structure Of The Pho85-pho80 Cdk-cyclin Complex Of The Phosphate-responsive Signal Transduction Pathway

Chain C, Structure Of The Pho85-pho80 Cdk-cyclin Complex Of The Phosphate-responsive Signal Transduction Pathway

Chain A, Structure Of The Pho85-Pho80 Cdk-Cyclin Complex Of The Phosphate- Responsive Signal Transduction Pathway With Bound Atp-Gamma-S

Chain C, Structure Of The Pho85-Pho80 Cdk-Cyclin Complex Of The Phosphate- Responsive Signal Transduction Pathway With Bound Atp-Gamma-S

++Y+ L  +G G YG+V  A + +T   VA+K++              RE+ LLK +KH+N++ L DV    + L       LV      DL      C   L  + V+  ++Q+L+GL + HS +++HRDLKP NL +N + ELK+ +FGLAR     +  Y   V T WYR P+++     Y+ ++D+WS GCI AEL   GR LFPG D  DQLK I RL+GTP  E    ++     +Y          +  NV    N    DLL+ +L  +  +RI+A +AL H YF+ +  P

ChainA, Structural Mechanism For The Inhibition Of Cdk5-P25 By Roscovitine, Aloisine And Indirubin.

Chain B, Structural Mechanism For The Inhibition Of Cdk5-P25 By Roscovitine, Aloisine And Indirubin.

Chain A, Structural Mechanism For The Inhibition Of Cdk5-P25 By Roscovitine, Aloisine And Indirubin.

Chain A, Structural Mechanism For The Inhibition Of Cd5-P25 From The Roscovitine, Aloisine And Indirubin.

Chain B, Structural Mechanism For The Inhibition Of Cd5-P25 From The Roscovitine, Aloisine And Indirubin.

Chain A, Crystal Structure Of Cdk5:p25 In Complex With An Atp Analogue

Chain B, Crystal Structure Of Cdk5:p25 In Complex With An Atp Analogue

++Y+ L  +G G YG+V  A + +T   VA+K++              RE+ LLK +KH+N++ L DV    + L       LV      DL      C   L  + V+  ++Q+L+GL + HS +++HRDLKP NL +N + ELK+ DFGLAR     +  Y   V T WYR P+++     Y+ ++D+WS GCI AEL    R LFPG D  DQLK I RL+GTP  E    ++     +Y          +  NV    N    DLL+ +L  +  +RI+A +AL H YF+ +  P

Chain B, Structure And Regulation Of The Cdk5-P25(Nck5a) Complex

E+Y+NL  VG G+YG V    +  TG  VA+KK        +  K   RE++LLK ++HEN++ LL+V    +    + EF     V H +  DL   +    L    VQ  ++QI+ G+ + HS +IIHRD+KP N+ V++   +K+ DFG AR         DDE    VATRWYRAPE+++  + Y + VD+W++GC++ E+  G  LFPG   IDQL  I+  +G     L+ +      +N + +  ++P++         +   + + +DL +K L +D DKR   A+ L H +F

Chain A, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312

Chain B, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312